Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028174 | 0.91 | TERT (0.62) | TERTDRD4SSTR3HDAC1 | |
| SCHEMBL7529702 | 0.85 | TERT (0.54) | TERTALDH1A1KDM4EALOX12 | |
| SCHEMBL6786390 | 0.85 | TERT (0.60) | TERTALDH1A1KDM4EALOX12 | |
| SCHEMBL6784228 | 0.85 | TERT (0.53) | TERTDRD4ALDH1A1KDM4EALOX12 | |
| SCHEMBL7531820 | 0.84 | TERT (0.55) | TERTALDH1A1KDM4EALOX12 | |
| SCHEMBL6785713 | 0.84 | TERT (0.52) | TERTDRD4ALDH1A1KDM4EALOX12 | |
| SCHEMBL6784963 | 0.83 | TERT (0.53) | TERTDRD4ALDH1A1KDM4EALOX12 | |
| SCHEMBL7530029 | 0.82 | TERT (0.55) | TERTDRD4ALDH1A1KDM4E | |
| SCHEMBL7527436 | 0.82 | TERT (0.56) | TERTALDH1A1KDM4EALOX12 | |
| SCHEMBL6784006 | 0.81 | TERT (0.55) | TERTDRD4ALDH1A1KDM4EALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492547-B2 | E.G., TRANS-3-NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-5-DIMETHYLAMINOMETHYL-PHENYL)-AMIDE; ANTITUMOR, ANTICARCINOGENIC AGENTS; TELOMERASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20020128495-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128495-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof | ASS1, ADCY1, SUCNR1 | TERT 4716/4885DRD4 2515/4885SSTR3 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.